Krystal Biotech, Inc. (KRYS)
Company Description
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States.
It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb.
Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Country | United States |
Founded | 2015 |
IPO Date | Sep 20, 2017 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 229 |
CEO | Krish S. Krishnan M.B.A., M.S. |
Contact Details
Address: 2100 Wharton Street, Suite 701 Pittsburgh, Pennsylvania 15203 United States | |
Phone | (412) 586-5830 |
Website | krystalbio.com |
Stock Details
Ticker Symbol | KRYS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001711279 |
CUSIP Number | 501147102 |
ISIN Number | US5011471027 |
Employer ID | 82-1080209 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Krish S. Krishnan M.B.A., M.S. | Founder, Chairman, President and Chief Executive Officer |
Suma M. Krishnan | Founder, Chief Operating Officer, President of Research & Development and Director |
Kathryn A. Romano | Executive Vice President and Chief Accounting Officer |
John Thomas | General Counsel and Corporate Secretary |
John Karakkal | Vice President of North American Sales and Marketing |
Christine Wilson | Head of U.S. Sales and Marketing |
Josh Suskin | Director of Human Resources and Operations |
Dr. Hubert C. Chen M.D. | Senior Vice President of Clinical Development |
Laurent Goux | Senior Vice President and GM of Europe |
Ram Kamineni | Senior Vice President of CMC and Technical Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 11, 2024 | 144 | Filing |
Mar 11, 2024 | 144 | Filing |
Feb 28, 2024 | 144 | Filing |
Feb 26, 2024 | 144 | Filing |
Feb 26, 2024 | 8-K | Current Report |
Feb 26, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Feb 26, 2024 | 10-K | Annual Report |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |